Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Innovative Biopharmaceutical Company, Domainex, has core intellectual property rights granted for Eu

Domainex Ltd (Domainex), an innovative biopharmaceutical company, today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

Based in London and Cambridge, Domainex is a research company developing a pipeline of pre-clinical drugs and targets, specializing in the development of novel drug targets reached by the CDH technology. The Company is also providing its unique structural biology and chemistry services to major pharmaceutical and biotechnology firms.

The vast amount of information available in the post-genomic era means that there are many highly attractive protein targets known to the pharmaceutical industry where an inability to supply of protein has prevented their use in drug discovery. Domainex has closed this ‘discovery gap’ with its unique Combinatorial Domain Hunting (CDH) technology which enables the cloning and expression of recombinant proteins, or parts of proteins (domains), from challenging molecular targets. These proteins are then screened to select soluble, stable protein domains that are ideal reagents for use in drug discovery programmes.

Domainex has already used its CDH protein expression platform to successfully tackle a series of difficult target proteins and has fulfilled commercial contracts with a number of major pharmaceutical companies, such as leading global firm, UCB.

Dr Eddy Littler, Chief Executive Officer of Domainex, said: “We are delighted to have had our CDH patent granted in Europe. These intellectual property rights are central to Domainex’s proprietary position on CDH and its application to the cloning and expression of challenging therapeutic targets. The application of the CDH technology in client projects is now an important part of our revenue stream - during 2008 we have already secured contracts for development work on four therapeutic targets and anticipate concluding several more over the next few months.

“The application of the CDH technology within our internal portfolio allows Domainex to access attractive therapeutic targets which are impossible to approach by other technologies. We also have a granted Australian patent for CDH and pending CDH patent applications in the USA and several other territories - we look forward to the successful grant of these applications in due course.”

Keith Powell, Chairman of Domainex, said: “It is great to see the core elements of a successful business coming together at Domainex - with the provision of targets and chemistry, the Company is well placed to be an invention engine for novel small molecule drugs.”

Domainex’s portfolio will have an initial focus on targets for cancer treatments and the Company has started to discuss these targets with pharmaceutical companies with a view to future out-licensing.

Domainex also provides comprehensive chemistry services to biotech and pharmaceutical firms involved in drug discovery. It has laboratories on the Cambridge Science Park, and its scientific operations are managed by Research Director, Dr Trevor Perrior, a highly experienced scientist who has been responsible for the discovery of several medicines.

- ENDS -
Editors Notes
Press enquiries to: Margaret Henry, PR Consultant.
Tel: +44 (0) 1865 811199 E-mail:

Photo available on request
Dr Eddy Littler, Chief Executive Officer of Domainex Ltd, which has announced the grant of a European patent for its unique Combinatorial Domain Hunting technology.

About Domainex Ltd
Founded in 2002, Domainex is a spin-out company from University College London (UCL), Birkbeck, University of London and The Institute of Cancer Research that specializes in the provision of combinatorial domain hunting and medicinal chemistry services to large pharmaceutical and biotechnology companies and is also developing a pipeline of pre-clinical drugs and targets.

Domainex generates protein domains from challenging molecular targets using a patented technology known as Combinatorial Domain Hunting (CDH) so that they may be expressed in a form suitable for use in drug discovery programmes. The CDH technology is based on research conducted by Professor Paul Driscoll, Professor Laurence Pearl, Dr Chris Prodromou and Dr Renos Savva, at UCL, The Institute for Cancer Research and Birkbeck, University of London.
CDH generates a large number of random genetic variants on proteins in a directed manner. These variants are cloned and expressed in E.coli, and then these variants are screened to detect those which produce the highest level of soluble and suitable protein domains. These domains are ideal reagents for drug discovery.

Using its CDH technology, Domainex has initiated a number of drug discovery projects focused on highly attractive target sites called nucleotide binding domains (NBDs) found in many highly validated targets for drug discovery. The Company is now focusing on targets where the CDH technology and its medicinal chemistry expertise give Domainex a strong competitive advantage and which are of interest to large pharmaceutical companies.

Domainex’s management team has substantial experience of both major pharmaceutical and biotechnology companies. The team is led by CEO, Dr Eddy Littler, an internationally recognized expert in virology. His former positions include Head of the Molecular Sciences Unit at Wellcome Research, with responsibility for virology and gene therapy of cancer programmes, and Head of Antiviral Research Unit at GlaxoWellcome, overseeing hepatitis C virus, respiratory viruses and DNA vaccine programmes. He also played a major part in the development and out-licensing of Medivir’s hepatitis C and HIV programmes.

Chairman, Dr Keith Powell, has almost 30 years experience in Biotechnology. He has held senior roles at Zeneca including Head of Discovery, Head of Biotechnology and Head of Intellectual Property. He led the development of the small molecule business at Maxygen which was spun out as Codexis, and since 2004 has worked with BBSF developing spin-out companies including Spear, Polytherics and Domainex. He has raised more than $16 million in VC funding and more than $50 million in partnering deals with pharmaceutical companies.

Founder and CSO, Prof Laurence Pearl, is Professor of Crystallography and Co-Chairman of the Section of Structural Biology at The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea which has an international reputation in studies of DNA repair and molecular chaperones.

The Research Director, Dr Trevor Perrior, held a number of senior R&D roles in pharmaceutical and biotechnology companies ICI, AstraZeneca and Celltech, leading teams that have delivered six development programmes (some with multiple candidates) across several therapeutic areas. His areas of expertise also include pre-clinical drug development.

The Non-Executive Directors include: Prof Salvador Moncada, an internationally renowned scientific leader whose positions include Director of Research at the Wellcome Research UK and Director of the Wolfson Institute for BioMedical Research (UCL); Edward Rudd, co-founder of Longbow Capital LLP, and Stéphane Méry, Director of Healthcare Investments at Noble Fund Managers who is also a Doctor in Veterinary Medicine.

Domainex has its registered office at the London Bioscience Innovation Centre and is based on the Cambridge Science Park. The Company employs 20 staff.
For more information:

Publisher Contact Information:

Domainex Ltd
+ 44 (0)1865 811199

Company profile of Domainex Ltd
Past press releases of Domainex Ltd.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jul 23€23.0MArtificial Intelligence
Jul 22€20.0MKnowledge management
Jul 5€110.0MOther Biotechnology & Healthcare
Jul 5€13.0MInternet services
Jul 3€3.7MMedical devices
Jul 3€27.0MPayment software

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.